Jazz Pharmaceuticals/$JAZZ
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
2,800
ISIN
IE00B4Q5ZN47
Website
JAZZ Metrics
BasicAdvanced
$6.8B
14.98
$7.51
0.32
-
Price and volume
Market cap
$6.8B
Beta
0.32
52-week high
$148.06
52-week low
$95.49
Average daily volume
708K
Financial strength
Current ratio
3.376
Quick ratio
2.638
Long term debt to equity
128.752
Total debt to equity
129.821
Interest coverage (TTM)
2.20%
Profitability
EBITDA (TTM)
1,389.267
Gross margin (TTM)
92.15%
Net profit margin (TTM)
11.86%
Operating margin (TTM)
17.97%
Effective tax rate (TTM)
-33.47%
Revenue per employee (TTM)
$1,450,000
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
12.25%
Valuation
Price to earnings (TTM)
14.984
Price to revenue (TTM)
1.7
Price to book
1.66
Price to tangible book (TTM)
-2.98
Price to free cash flow (TTM)
4.576
Free cash flow yield (TTM)
21.85%
Free cash flow per share (TTM)
2,457.98%
Growth
Revenue change (TTM)
5.76%
Earnings per share change (TTM)
49.21%
3-year revenue growth (CAGR)
7.19%
10-year revenue growth (CAGR)
12.65%
3-year earnings per share growth (CAGR)
0.64%
10-year earnings per share growth (CAGR)
8.03%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Bulls say / Bears say
Jazz Pharmaceuticals received European Commission marketing authorization for Ziihera® (zanidatamab) for the treatment of advanced HER2-positive biliary tract cancer, expanding its oncology portfolio. (Jazz Pharmaceuticals News)
The company reported record third-quarter revenue of $1.05 billion, a 14% year-over-year increase, driven by strong sales of key therapies like Xywav, Epidiolex, and Rylaze. (Benzinga)
Jazz Pharmaceuticals announced positive top-line results from the phase III IMforte study, showing that the combination of Zepzelca and Tecentriq significantly improved survival in extensive-stage small cell lung cancer patients. (Nasdaq)
Jazz Pharmaceuticals' phase II study evaluating JPZ150 for post-traumatic stress disorder failed to meet its primary endpoint, leading the company to halt further development of the drug in this indication. (Nasdaq)
The company settled a class action lawsuit alleging collusion to delay a generic version of its narcolepsy drug Xyrem, agreeing to pay $145 million, which could impact its financial position. (Reuters)
Cantor Fitzgerald downgraded Jazz Pharmaceuticals to a 'Neutral' rating, indicating potential concerns about the company's future growth prospects. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
JAZZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $6.8B as of July 11, 2025.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 14.98 as of July 11, 2025.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.